PFE FDA calendar & decision history Roivant/Priovant · 1 upcoming · 9 past FDA decisions
Upcoming FDA catalysts PFE · Sep 30, 2026 Brepocitinib (VALOR) — Dermatomyositis FDA decision history (9) Jul 10, 2026✓ Approved KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYN Jun 24, 2026✓ Approved IBRANCE (palbociclib) in combi Jun 8, 2026✓ Approved HYMPAVZI (marstacimab) May 1, 2026✓ Approved VEPPANU (vepdegestrant) - (VER Feb 24, 2026✓ Approved BRAFTOVI (encorafenib) in comb Dec 17, 2025✕ CRL FDA decision Nov 21, 2025✓ Approved FDA decision Aug 27, 2025✓ Approved FDA decision Feb 12, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates PFE's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio